Table 3 Tolerability of baricitinib before and after temporary interruption based on adverse event terms reported by ≥ 2% of patients
n (%) | First 4 weeks after initiating baricitinib (N = 318) | First 4 weeks after restarting baricitinib (N = 318) |
|---|---|---|
Patients with ≥ 1 TEAE | 160 (50.3) | 80 (25.2) |
Upper respiratory tract infection | 15 (4.7) | 5 (1.6) |
Headache | 13 (4.1) | 2 (0.6) |
Blood creatine phosphokinase increased | 10 (3.1) | 1 (0.3) |
Diarrhea | 9 (2.8) | 1 (0.3) |
Bronchitis | 8 (2.5) | 3 (0.9) |
Nausea | 8 (2.5) | 2 (0.6) |
Constipation | 7 (2.2) | 0 |
Gastroenteritis | 7 (2.2) | 0 |
Urinary tract infection | 7 (2.2) | 1 (0.3) |